RMA Hunter Valley 2020

DermaSensor’s revolutionary skin cancer technology shines a light on melanoma detection at the Rural Medicine Australia Conference in the Hunter Valley

HUNTER VALLEY, Australia, 28th-31st October 2020: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, will show its revolutionary skin cancer detection technology to clinicians and healthcare professionals at the Rural Medicine Australia conference today.

This annual conference and research/scientific health forum is the peak national event for rural and remote doctors of Australia. It is hosted by the Australian College of Rural and Remote Medicine (ACRRM) and the Rural Doctors Association of Australia (RDAA). Almost 900 rural doctors, medical students and other rural health stakeholders from across the country will attend the event.

Rural Medicine Australia 2020 has a packed program full of innovative and informative presentations, interactive workshops and social events, along with many exhibitions.

Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor team will present the DermaSensor device, a revolutionary, world-first technology, designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions.

“We are pleased to return to the Rural Medicine Australia event to present DermaSensor’s technology and explain how it can help rural doctors quickly and effectively check for skin cancer,” explains Kevin.

DermaSensor has managed to miniaturise a device that uses Elastic Scattering Spectroscopy into a handheld device. The technology was pioneered at Boston University and University College London. It uses light to evaluate cellular and subcellular structures of the skin.

The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. A proprietary algorithm instantly analyses the reflected photons to provide a simple “Higher Risk” or “Lower Risk” output to support a physician’s referral decision. This provides an immediate, objective result that’s typically more accurate than visual assessment alone.

DermaSensor complements the expertise and experience to improve the way general practitioners assess the skin.

The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. The DermaSensor device is low-cost and easy-to-use. It enables healthcare providers and patients to receive fast and accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.

Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and medical practitioners may spend less time on lengthy procedures.

Scroll to Top